Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
Liver transplantation is currently the only effective way to treat end-stage liver
disease.The shortage of donor liver is still the major problem. Incidence of HBcAb+ varies
between different regions. The HBcAb positive rate could be as high as 52% in China.HBcAb
positive donor liver may enlarge donor pool and thus save ESLD patients. However, the use of
HBcAb positive donor liver may induce HBV infection in hepatitis B negative recipient after
liver transplantation. Tenofovir alafenamide (TAF) has better stability in plasma and higher
liver targeting property in comparison with tenofovir (TDF), with an extra amide bond, which
allows strong antiviral effect with much less doses and reducing the renal and bone injury.
Our study intends to evaluate the efficacy and safety of HBV prophylaxis treatment of TAF in
HBV negative patients after receiving HBcAb positive donor livers.